‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The Federal Trade Commission and seven states say Shkreli should be held in contempt
The Federal Trade Commission and seven states say Shkreli should be held in contempt This story matters for Finance & Markets readers tracking trade. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. Trade-News.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily trade signal